Big Pharma Has Eyes on Cerenis' HDL Drug

French drug developer Cerenis has begun mid-stage trials of a new class of drug that behaves like high-density lipoprotein (HDL)--the good cholesterol that can clear arteries of the plaque that causes heart attacks. The tiny drug developer has already been approached by several large pharma companies looking to grab a piece of the pie early, while the cost of entry is relatively cheap. But Cerenis execs have decided to wait until after they have mid-stage data in hand to consider a deal.

"We think we can